TargetRx launches the FieldPerformanceAdvantage tool

Share this article:
TargetRx unveiled FieldPerformanceAdvantage, an industry tool designed to help pharmaceutical and biotech companies understand how in-field sales and marketing initiatives are actually performing at driving prescribing and how to quickly improve these initiatives as the market continues to undergo rapid change.

FieldPerformanceAdvantage measures the effectiveness of sales and marketing activities at driving prescribing, in addition to measuring utilization and sales rep activities.

By tracking all aspects of rep interactions with physicians and then isolating the impact of these interactions on actual prescribing behavior, TargetRx has identified the five actionable drivers of prescribing that have consistently shown the greatest impact on prescribing within and across categories. 

These drivers are similar to those in previously released Sales and Marketing Quality Reports. 

The five drivers are classified into two categories: Foundation Drivers—The core platform for a brand's in-field promotional activities, including messages and sales reps. Execution Drivers—Actions that, when executed often and effectively, have proven to drive prescribing behavior, including patient identification, detail piece/communication aids, and closing. 

Through FieldPerformanceAdvantage, each of these drivers for a brand can be measured, managed, and improved, allowing sales and marketing management teams to track progress and seize opportunities to increase effectiveness.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?